Literature DB >> 26905032

Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer.

Maria De Santis1, Fred Saad2.   

Abstract

Corticosteroids have been used in combination with chemotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for more than three decades, particularly to treat pain, inflammation, and edema. More recently, they have been used in combination with hormonal agents. The importance of corticosteroids in mCRPC is due to their ability to manage adverse effects, reduce symptoms, and improve patients' quality of life. The appropriate selection of available options in mCRPC should be based on careful consideration of a patient's profile and comorbidities. This review provides an overview of the role of corticosteroids in treating mCRPC for the practicing urologist.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26905032     DOI： 10.1016/j.urology.2016.02.010

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.

Authors:  Jieping Hu; Qingke Chen
Journal:  Int Urol Nephrol       Date:  2016-12-16       Impact factor: 2.370

2.  Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.

Authors:  Bodine P S Belderbos; Koen G A M Hussaarts; Leonie J van Harten; Esther Oomen-de Hoop; Peter de Bruijn; Paul Hamberg; Robbert J van Alphen; Brigitte C M Haberkorn; Martijn P Lolkema; Ronald de Wit; Robert J van Soest; Ron H J Mathijssen
Journal:  Br J Clin Pharmacol       Date:  2019-03-21       Impact factor: 4.335

3.  PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report.

Authors:  Tomonori Kato; Satoko Kojima; Ayumi Fujimoto; Kotaro Otsuka; Takahito Suyama; Kyokushin Hou; Kazuhiro Araki; Hiroshi Masuda; Kazuto Yamazaki; Akira Komiya; Yukio Naya
Journal:  Oncol Lett       Date:  2018-08-17       Impact factor: 2.967

4.  Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

Authors:  Neil M Schultz; David F Penson; Samuel Wilson; Yan Song; Hongbo Yang; Krishnan Ramaswamy; Benjamin Lowentritt
Journal:  Drug Saf       Date:  2020-01       Impact factor: 5.606

5.  Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

Authors:  Fernando Cotait Maluf; Felipe Moraes Toledo Pereira; Adriano Gonçalves Silva; Aldo Lourenço Abbade Dettino; Ana Paula Garcia Cardoso; André Seeke Sasse; Andrey Soares; Ariel Galapo Kann; Daniel Herchenhorn; Denis Leonardo Fontes Jardim; Diego Emilio Lopera Cortés; Fábio Roberto Kater; Igor A Protzner Morbeck; João Francisco Navarro Reolon; José Augusto Rinck; Juan Jose Zarbá; Juan Pablo Sade; Karine Martins da Trindade; Leonardo Atem G A Costa; Lucas V Dos Santos; Manuel Caitano Maia; Mariana Bruno Siqueira; Silke Gillessen
Journal:  JCO Glob Oncol       Date:  2021-04

Review 6.  Exploring the therapeutic potential of Neem (Azadirachta Indica) for the treatment of prostate cancer: a literature review.

Authors:  Neelu Batra; Vigneshwari Easwar Kumar; Roshni Nambiar; Cristabelle De Souza; Ashley Yuen; Uyen Le; Rashmi Verma; Paramita M Ghosh; Ruth L Vinall
Journal:  Ann Transl Med       Date:  2022-07

Review 7.  Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.

Authors:  Amani Yehya; Fatima Ghamlouche; Amin Zahwe; Yousef Zeid; Kevork Wakimian; Deborah Mukherji; Wassim Abou-Kheir
Journal:  Cancer Drug Resist       Date:  2022-06-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.